LXR

Liver X receptor



LXRs (Liver X Receptor α and β) are nuclear receptors that act as ligand-activated transcription factors. LXR activation causes upregulation of genes involved in reverse cholesterol transport (RCT), including ABCA1 and ABCG1 transporters, in macrophage and intestine.

LXRα/β are ligand-activated transcription factors of the nuclear hormone receptor superfamily that stimulate transcription of several genes, including ABCA1 and apoE. LXRα and LXRβ respond to the same oxysterol ligands and activate transcription as obligate heterodimeric complexes with retinoid X receptors.

Synthetic LXR agonists activate both LXRα and LXRβ, cross the blood-brain barrier, and efficiently induce expression of LXR target genes including ABCA1 and apoE.

LXR Inhibitors & Modulators

(20S)-Protopanaxatriol

(20(S)-APPT; g-PPT)

Cat. No.: HY-N0835

Bioactivity: (20S)-Protopanaxatriol is a metabolite of ginsenoside, works through the **glucocorticoid receptor (GR)** and **oestrogen receptor (ER)**, and is also a **LXRα** inhibitor.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



24-Hydroxycholesterol

Cat. No.: HY-N2370

Bioactivity: 24-Hydroxycholesterol is a natural sterol, which serves as a positive allosteric modulator of **N-Methyl-d-Aspartate (NMDA) receptorsR**, and a potent activator of the transcription factors **LXR**.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg



27-Hydroxycholesterol

Cat. No.: HY-N2371

Bioactivity: 27-Hydroxycholesterol is a selective **estrogen receptor** modulator and an agonist of the **liver X receptor**.

Purity: 99.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ876

Cat. No.: HY-18282

Bioactivity: AZ876 is a novel high-affinity LXR agonist.

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



BMS-779788

(EXEL04286652; XL-652; BMS-788)

Cat. No.: HY-19919

Bioactivity: BMS-779788 is a **LXR** partial agonist with **IC_{50}** values of 68 nM for LXR α and 14 nM for LXR β.

Purity: 98.0%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



GSK2033

Cat. No.: HY-108688

Bioactivity: GSK2033 is a **LXR** antagonist with **pIC_{50}**s of 7 and 7.4 for **LXRα** or **LXRβ**, respectively.

Purity: 98.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GW3965

Cat. No.: HY-10627

Bioactivity: GW3965 is a potent, selective **LXR** agonist for hLXRα and hLXRβ with **EC_{50}** of 190 and 30 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



GW3965 hydrochloride

Cat. No.: HY-10627A

Bioactivity: GW3965 hydrochloride is a potent and selective **LXR** agonist with **EC_{50}**s of 190 and 30 nM for hLXRα and hLXRβ , respectively.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



LXR-623

(WAY 252623)

Cat. No.: HY-10629

Bioactivity: LXR-623 is a brain-penetrant partial **LXRα** and full **LXRβ** agonist, with **IC_{50}**s of 24 nM and 179 nM, respectively.

Purity: 99.40%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Nagilactone B

Cat. No.: HY-N3216

Bioactivity: Nagilactone B, extracted from the root bark of Podocarpus nagi, is a liver X receptor (**LXR**) agonist.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

RGX-104

Cat. No.: HY-111498

Bioactivity: RGX-104 is a small-molecule **LXR** agonist that modulates innate immunity via transcriptional activation of the ApoE gene.

Purity: 99.81%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RGX-104 free Acid

Cat. No.: HY-111498A

Bioactivity: RGX-104 (free base) is an orally bioavailable and potent liver-X nuclear hormone receptor **(LXR)** agonist that modulates innate immunity via transcriptional activation of the ApoE gene.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Rovazolac

Cat. No.: HY-109073

Bioactivity: Rovazolac is a **liver x receptor (LXR)** modulator extracted from patent WO2013130892A1.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



SR9238

Cat. No.: HY-101442

Bioactivity: SR9238 is a synthetic **LXR** antagonist with **IC_{50}**s of 214 nM and 43 nM for **LXRα** and **LXRβ**, respectively.

Purity: 99.53%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg



SR9243

Cat. No.: HY-16972

Bioactivity: SR9243 is a **liver-X-receptor (LXR)** inverse agonist that induces LXR-corepressor interaction.

Purity: 96.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



T0901317

Cat. No.: HY-10626

Bioactivity: T0901317 is a potent and selective agonist for **LXR** and **FXR**, with **EC_{50}**s of 50 nM and 5 μM, respectively.

Purity: 99.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg



XL041

(BMS-852927)

Cat. No.: HY-101973

Bioactivity: BMS-852927 is an **LXRβ**-selective agonist.

Purity: 99.11%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg